DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2215118/here-s-why-investors-may-bet-on-biomarin-bmrn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2215118 Jan 24, 2024 - Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever. 0

https://www.zacks.com/stock/news/2227844/seeking-clues-to-biomarin-bmrn-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2227844 Feb 19, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for BioMarin (BMRN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2228608/merus-n-v-mrus-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2228608 Feb 20, 2024 - Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2230527/here-s-what-key-metrics-tell-us-about-biomarin-bmrn-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2230527 Feb 22, 2024 - Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2212996/centene-cnc-chosen-to-serve-new-hampshire-s-medicaid-members?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212996 Jan 19, 2024 - Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members. 0

https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328 Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance. 0

https://www.zacks.com/stock/news/2247354/atara-biotherapeutics-atra-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2247354 Mar 28, 2024 - Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 8.20% and 73.91%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2256912/biomarin-pharmaceutical-bmrn-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2256912 Apr 17, 2024 - BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0